ILV-094 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis5

46. Malignant rheumatoid arthritis


Clinical trials : 4,325 Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-006936-37-BE
(EUCTR)
24/08/200908/04/2009A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Background of MethotrexateA Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Background of Methotrexate Rheumatoid Arthritis (RA)
MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis
Product Name: ILV-094
Product Code: ILV-094
Other descriptive name: Recombinant human anti IL-22 monoclonal antibody IgG1
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and DevelopmentNULLNot RecruitingFemale: yes
Male: yes
180Phase 2Hungary;Belgium;Netherlands;Germany
2EUCTR2008-006936-37-DE
(EUCTR)
03/08/200916/04/2009A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Background of MethotrexateA Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Background of Methotrexate Rheumatoid Arthritis (RA)
MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis
Product Name: ILV-094
Product Code: ILV-094
Other descriptive name: Recombinant human anti IL-22 monoclonal antibody IgG1
Wyeth Pharmaceuticals Inc., acting through its division Wyeth Research, a Pfizer companyNULLNot RecruitingFemale: yes
Male: yes
180Hungary;Germany;Netherlands;Belgium
3EUCTR2008-006936-37-NL
(EUCTR)
27/07/200929/04/2009A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Background of MethotrexateA Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Background of Methotrexate Rheumatoid Arthritis (RA)
MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis
Product Name: ILV-094
Other descriptive name: Recombinant human anti IL-22 monoclonal antibody IgG1
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and DevelopmentNULLNot RecruitingFemale: yes
Male: yes
120Hungary;Germany;Netherlands;Belgium
4NCT00883896
(ClinicalTrials.gov)
June 200917/4/2009Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid ArthritisA Randomized, Parallel, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of ILV-094 Administered Subcutaneously To Subjects With Active Rheumatoid Arthritis On A Stable Background Of MethotrexateRheumatoid ArthritisOther: Placebo;Drug: ILV-094PfizerNULLCompleted18 YearsN/ABoth195Phase 2United States;Belgium;Colombia;Croatia;Germany;Hungary;Japan;Mexico;Netherlands;Romania;Russian Federation;Denmark
5EUCTR2008-006936-37-HU
(EUCTR)
25/03/200902/03/2009A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Background of MethotrexateA Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Background of Methotrexate Rheumatoid Arthritis (RA)
MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis
Product Name: ILV-094
Product Code: ILV-094
Other descriptive name: Recombinant human anti IL-22 monoclonal antibody IgG1
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and DevelopmentNULLNot RecruitingFemale: yes
Male: yes
180Hungary;Germany;Netherlands;Belgium